{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:50:16Z","timestamp":1740142216039,"version":"3.37.3"},"reference-count":48,"publisher":"Informa UK Limited","issue":"33","funder":[{"name":"Astra Zeneca"},{"name":"Clovis"},{"DOI":"10.13039\/100012634","name":"Novocure","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012634","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018096","name":"GOG Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018096","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck"},{"DOI":"10.13039\/100016859","name":"Mersana","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016859","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Agenus"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.2217\/fon-2020-0538","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T10:40:45Z","timestamp":1599129645000},"page":"2701-2711","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Niraparib in the Treatment of Previously Treated Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer"],"prefix":"10.1080","volume":"16","author":[{"given":"BJ","family":"Rimel","sequence":"first","affiliation":[{"name":"Cedars-Sinai Medical Center,Department of Obstetrics & Gynecology,Division of Gynecologic Oncology, \rLos Angeles,CA90048,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Dockery","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill,Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, \rChapel Hill,NC27599,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M","family":"Randall","sequence":"additional","affiliation":[{"name":"Massey Cancer Center, Virginia Commonwealth University, \rRichmond,VA23298,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-0718","authenticated-orcid":false,"given":"Kathleen","family":"Moore","sequence":"additional","affiliation":[{"name":"The Stephenson Cancer Center,The University of Oklahoma, \rOklahoma City,OK73104,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"U.S. Cancer Statistics Working Group\n. US Cancer Statistics Data Visualizations Tool based on November 2018 submission data (1999\u20132016). (2019). www.cdc.gv\/cancer\/dataviz"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.04.019"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-020-00301-8"},{"key":"e_1_3_3_6_1","unstructured":"FDA label for olaparib (2020). www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf#page=1"},{"key":"e_1_3_3_7_1","unstructured":"FDA approval for rubraca. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209115s003lbl.pdf"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00867-4"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02050"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2007.113"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0714"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1038"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-020-00390-7"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.10.040"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10760"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.21"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901188v"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3455-x"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26354"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70240-7"},{"key":"e_1_3_3_22_1","first-page":"28","article-title":"Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly(ADP-ribose) polymerase (PARP)-1 and-2 inhibitor","author":"Zhang ZY","year":"2017","unstructured":"Zhang ZY . Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly(ADP-ribose) polymerase (PARP)-1 and-2 inhibitor. Ann. Oncol.28 (2017).","journal-title":"Ann. Oncol."},{"key":"e_1_3_3_23_1","first-page":"28","article-title":"The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: results from the ENGOT-OV16\/NOVA trial","volume":"9","author":"Wang J","year":"2017","unstructured":"Wang J . The exposure-response relationship of niraparib in patients with gBRCAmut and non-gBRCAmut: results from the ENGOT-OV16\/NOVA trial. Ann. Oncol.9, 28 (2017).","journal-title":"Ann. Oncol."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx376.050"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30029-4"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.12.009"},{"key":"e_1_3_3_29_1","unstructured":"FDA label for niraparib. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208447s015s017lbledt.pdf"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy181"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30333-4"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0114-z"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01121-10"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-13-0628"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.19.8504-8518.2004"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38534-6"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01883-9"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.5555"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30515-7"},{"issue":"6003","key":"e_1_3_3_42_1","article-title":"A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer","volume":"38","author":"Liu JF","year":"2020","unstructured":"Liu JF , BradyM, MatulonisUAet al. A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. J. Clin. Oncol.38(Suppl. abstr. 6003), (2020).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.106"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.10.003"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0715"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05564-z"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1915108116"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0146"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M507075200"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30905-7"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2020-0538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:15Z","timestamp":1719124935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-0538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":48,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.2217\/fon-2020-0538"],"URL":"https:\/\/doi.org\/10.2217\/fon-2020-0538","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}